Total Payments
$558,658
2024 Payments
$151,788
Companies
45
Transactions
1,447
Medicare Patients
3,480
Medicare Billing
$564,433
Payment Breakdown by Category
Other$385,162 (68.9%)
Consulting$92,247 (16.5%)
Travel$51,779 (9.3%)
Food & Beverage$27,721 (5.0%)
Research$1,515 (0.3%)
Education$233.03 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $351,266 | 166 | 62.9% |
| Consulting Fee | $92,247 | 43 | 16.5% |
| Travel and Lodging | $51,779 | 245 | 9.3% |
| Honoraria | $33,896 | 14 | 6.1% |
| Food and Beverage | $27,721 | 956 | 5.0% |
| Unspecified | $1,515 | 16 | 0.3% |
| Education | $233.03 | 7 | 0.0% |
Payments by Type
General
$557,143
1,431 transactions
Research
$1,515
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $143,688 | 188 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $134,495 | 322 | $0 (2024) |
| BioCryst US Sales Co., LLC | $69,565 | 101 | $0 (2024) |
| Pharming Healthcare, Inc. | $48,664 | 103 | $0 (2024) |
| Optinose US, Inc. | $37,685 | 86 | $0 (2024) |
| Shire North American Group Inc | $31,926 | 73 | $0 (2019) |
| CSL Behring | $30,623 | 89 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21,876 | 37 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $6,596 | 42 | $0 (2023) |
| Amgen Inc. | $6,196 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $151,788 | 283 | AstraZeneca Pharmaceuticals LP ($60,980) |
| 2023 | $60,030 | 190 | AstraZeneca Pharmaceuticals LP ($17,953) |
| 2022 | $114,365 | 262 | Takeda Pharmaceuticals U.S.A., Inc. ($40,853) |
| 2021 | $80,479 | 202 | Takeda Pharmaceuticals U.S.A., Inc. ($30,858) |
| 2020 | $28,694 | 109 | Takeda Pharmaceuticals U.S.A., Inc. ($18,495) |
| 2019 | $67,290 | 178 | Shire North American Group Inc ($27,450) |
| 2018 | $26,202 | 105 | CSL Behring ($6,824) |
| 2017 | $29,809 | 118 | CSL Behring ($10,940) |
All Payment Transactions
1,447 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: BIOLOGIC | ||||||
| 12/16/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $8.65 | General |
| Category: Immunology | ||||||
| 12/16/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $4.53 | General |
| Category: Immunology | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Optinose US, Inc. | Xhance (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,785.00 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/10/2024 | Optinose US, Inc. | Xhance (Drug) | Travel and Lodging | Cash or cash equivalent | $43.60 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/10/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Immunology and Neurology | ||||||
| 12/10/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,222.50 | General |
| Category: GENETIC DISEASE | ||||||
| 12/09/2024 | Grifols USA, LLC | Xembify (Biological) | Food and Beverage | In-kind items and services | $3.33 | General |
| Category: Immunology and Neurology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: Respiratory | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $10.72 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: Immunology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,222.50 | General |
| Category: GENETIC DISEASE | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,350.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $26.27 | General |
| Category: Immunology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | Cycle Pharmaceuticals Inc | Sajazir (Drug) | Food and Beverage | In-kind items and services | $38.39 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $31.54 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $13.40 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: GENETIC DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 | SANOFI US SERVICES INC. | $1,515 | 16 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 983 | 10,496 | $518,033 | $170,235 |
| 2022 | 13 | 935 | 13,718 | $668,823 | $232,156 |
| 2021 | 13 | 834 | 8,337 | $216,907 | $100,826 |
| 2020 | 9 | 728 | 5,974 | $134,042 | $61,215 |
Total Patients
3,480
Total Services
38,525
Medicare Billing
$564,433
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 12 | 3,405 | $284,723 | $77,248 | 27.1% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 82 | 3,290 | $62,820 | $35,012 | 55.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 148 | 234 | $55,010 | $21,956 | 39.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 156 | 194 | $29,626 | $11,010 | 37.2% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 79 | 1,213 | $30,325 | $9,476 | 31.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 160 | 277 | $18,698 | $5,150 | 27.5% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 27 | 1,193 | $9,783 | $3,255 | 33.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $7,960 | $3,100 | 38.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 21 | 153 | $8,384 | $1,461 | 17.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $3,696 | $1,160 | 31.4% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2023 | 236 | 473 | $4,730 | $878.26 | 18.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 17 | 19 | $2,278 | $528.66 | 23.2% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 12 | 4,711 | $431,023 | $123,961 | 28.8% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 82 | 4,814 | $92,760 | $52,902 | 57.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 204 | 307 | $35,305 | $18,542 | 52.5% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 81 | 1,379 | $34,475 | $10,623 | 30.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 94 | $15,510 | $8,645 | 55.7% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 152 | 268 | $18,090 | $4,830 | 26.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 41 | 41 | $6,765 | $3,236 | 47.8% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 32 | 1,412 | $11,578 | $2,893 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $4,962 | $2,327 | 46.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 20 | 209 | $10,894 | $2,080 | 19.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 25 | 27 | $3,124 | $801.87 | 25.7% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 12 | 113 | $1,107 | $719.73 | 65.0% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2022 | 191 | 323 | $3,230 | $594.62 | 18.4% |
About Dr. Andrew Smith, MD
Dr. Andrew Smith, MD is a Internal Medicine healthcare provider based in Sandy, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164468955.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Smith, MD has received a total of $558,658 in payments from pharmaceutical and medical device companies, with $151,788 received in 2024. These payments were reported across 1,447 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($351,266).
As a Medicare-enrolled provider, Smith has provided services to 3,480 Medicare beneficiaries, totaling 38,525 services with total Medicare billing of $564,433. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Allergy & Immunology
- Location Sandy, UT
- Active Since 06/21/2006
- Last Updated 10/14/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1164468955
Products in Payments
- CINRYZE (Drug) $115,053
- AIRSUPRA (Drug) $60,352
- RUCONEST (Biological) $48,664
- TAKHZYRO (Biological) $44,118
- ORLADEYO (Drug) $42,487
- Xhance (Drug) $37,685
- TEZSPIRE (Biological) $35,954
- Haegarda (Biological) $26,357
- Orladeyo (Drug) $19,362
- FASENRA (Biological) $10,852
- FASENRA (Drug) $10,146
- BEVESPI AEROSPHERE (Drug) $8,648
- SPIRIVA RESPIMAT (Drug) $7,435
- DUPIXENT (Biological) $4,549
- CINQAIR (Drug) $3,777
- CINQAIR (Biological) $2,577
- AYVAKIT (Drug) $2,554
- GENERAL - BRONCHIAL THERMOPLASTY (Device) $2,400
- VTAMA (Drug) $2,120
- SAR440340 (Drug) $1,515
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Sandy
Barbara Rizzardi, Md, MD
Internal Medicine — Payments: $266,089
Internal Medicine $266,089
Mark Jensen, D.o, D.O
Internal Medicine — Payments: $5,564
Internal Medicine $5,564
Zhenhao Liu, Md, MD
Internal Medicine — Payments: $2,124
Internal Medicine $2,124
Kevin Stigge, Md, MD
Internal Medicine — Payments: $1,730
Internal Medicine $1,730
Patrick Mcdermott, Md, MD
Internal Medicine — Payments: $1,285
Internal Medicine $1,285
Richard Whittington, Md, MD
Internal Medicine — Payments: $1,200
Internal Medicine $1,200